Literature DB >> 32744574

The Predictive Value of Sarcopenia and Its Individual Criteria for Cardiovascular and All-Cause Mortality in Suburb-dwelling Older Chinese.

P Han1, X Chen, X Yu, Y Zhang, P Song, M Cai, L Liang, Z Liang, R Yang, F Jin, L Wang, Q Guo.   

Abstract

OBJECTIVES: The aim of the present study is to investigate the associations between the Asian Working Group for Sarcopenia (AWGS) sarcopenic definition, and its individual criteria, and risk of cardiovascular disease (CVD) and all-cause mortality in the Chinese elderly.
METHODS: Longitudinal analysis of 1,264 participants aged 60 years or older at baseline (2013-2014) living in suburban areas, China. Sarcopenia was defined according to the recommended algorithm of AWGS. Muscle mass was measured by a direct segmental multifrequency bioelectrical impedance analysis. Muscle strength was assessed by handgrip strength, and physical performance measured via usual walking speed.
RESULTS: Cox proportional hazard models were used to assess the risk of CVD and all-cause mortality. After 40 months of follow-up, forty-eight deaths (4.2%) died in this cohort. The mortality rate with sarcopenia was 4.7% in men and 3.8% in women. After adjusting for potential confounders, the risk of all-cause death was 4.15 times higher in subjects with sarcopenia. Furthermore, low muscle mass (HR: 2.62, 95% CI 1.34-5.13) and low grip strength (HR: 5.79; 95% CI 2.28-14.71), but not walking speed, were found to be significantly associated with all-cause mortality. Risk of CVD mortality was significantly greater in sarcopenia. Low grip strength and low walking speed were associated with 11 times (HR: 11.03, 95% CI 1.58-77.02) and 13 times (HR: 13.02; 95% CI 1.18-143.78) higher risk of CVD mortality.
CONCLUSIONS: Sarcopenia and components of sarcopenia were associated with greater CVD and all-cause mortality. Pertinent prevention or rehabilitation programs projects should look to promote healthy aging in different types of sarcopenia group.

Entities:  

Keywords:  CVD mortality; Chinese; Sarcopenia; all-cause mortality; components

Mesh:

Year:  2020        PMID: 32744574     DOI: 10.1007/s12603-020-1390-8

Source DB:  PubMed          Journal:  J Nutr Health Aging        ISSN: 1279-7707            Impact factor:   4.075


  6 in total

Review 1.  Older cancer patients receiving radiotherapy: a systematic review for the role of sarcopenia in treatment outcomes.

Authors:  Nezahat Muge Catikkas; Zumrut Bahat; Meryem Merve Oren; Gulistan Bahat
Journal:  Aging Clin Exp Res       Date:  2022-02-15       Impact factor: 4.481

2.  Commentary: Association of Sarcopenia with Toxicity and Survival in Postoperative Recurrent Esophageal Squamous Cell Carcinoma Patients Receiving Chemoradiotherapy.

Authors:  Zumrut Bahat; Gulistan Bahat
Journal:  Front Oncol       Date:  2022-01-05       Impact factor: 6.244

3.  Relationship between serum creatinine to cystatin C ratio and subclinical atherosclerosis in patients with type 2 diabetes.

Authors:  Yoshitaka Hashimoto; Fuyuko Takahashi; Takuro Okamura; Takafumi Osaka; Hiroshi Okada; Takafumi Senmaru; Saori Majima; Emi Ushigome; Naoko Nakanishi; Mai Asano; Masahide Hamaguchi; Masahiro Yamazaki; Michiaki Fukui
Journal:  BMJ Open Diabetes Res Care       Date:  2022-06

Review 4.  An umbrella review of systematic reviews of β-hydroxy-β-methyl butyrate supplementation in ageing and clinical practice.

Authors:  Stuart M Phillips; Kyle J Lau; Alysha C D'Souza; Everson A Nunes
Journal:  J Cachexia Sarcopenia Muscle       Date:  2022-07-12       Impact factor: 12.063

5.  Association of sarcopenia with ideal cardiovascular health metrics among US adults: a cross-sectional study of NHANES data from 2011 to 2018.

Authors:  Weihua Chen; Shanshan Shi; Yizhou Jiang; Kaihong Chen; Ying Liao; Rongchong Huang; Kun Huang
Journal:  BMJ Open       Date:  2022-09-23       Impact factor: 3.006

6.  Association between sarcopenia and cardiovascular disease among middle-aged and older adults: Findings from the China health and retirement longitudinal study.

Authors:  Ke Gao; Li-Fei Cao; Wen-Zhuo Ma; Ya-Jie Gao; Miao-Sha Luo; Jiao Zhu; Tian Li; Dan Zhou
Journal:  EClinicalMedicine       Date:  2022-01-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.